Phospho-CAD (Ser1859) Antibody [C23K19]

Application: Reactivity: Human, Mouse, Rat

Lane 1: 293T, Lane 2: 293T (λ phosphatase treated)

Usage Information

Dilution
WB1:1000 IHC1:200

Application
WB, IHC

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
240 kDa

Datasheet & SDS

Biological Description

Specificity
Phospho-CAD (Ser1859) Antibody [C23K19] detects endogenous levels of total CAD protein only when it is phosphorylated at Ser1859.

Clone
C23K19

Synonym(s)
CAD protein; Carbamoyl-phosphate synthetase 2; Aspartate transcarbamylase; Dihydroorotase; CAD

Background
Phospho-CAD (Ser1859) functions as the activated form of the multifunctional CAD enzyme complex that catalyzes the initial three steps of de novo pyrimidine biosynthesis, converting glutamine to carbamoyl phosphate, then to carbamoyl aspartate, and finally to dihydroorotate en route to UMP production essential for RNA and DNA synthesis. CAD assembles as a hexameric structure with distinct catalytic domains for glutamine amidotransferase (GLNase), carbamoyl-phosphate synthetase (CPSase), aspartate transcarbamoylase (ATCase), and dihydroorotase (DHOase), where phosphorylation at Ser1859 within the CPSase domain stabilizes inter-subunit contacts to enhance enzymatic flux through allosteric relief of feedback inhibition by UTP. mTORC1 pathway activation transmits growth signals through S6K1 kinase to deposit this phosphate mark, promoting CAD oligomerization that accelerates glutamine-dependent CPSase activity and ATCase condensation while coordinating with pentose phosphate pathway flux to match nucleotide demand during S-phase progression. ERK1/2 phosphorylation at Thr456 drives nuclear translocation upon G1/S entry, positioning phospho-CAD to support replication fork progression and chromatin remodeling, with subsequent PKA-mediated Ser1406 phosphorylation facilitating cytoplasmic return as cells exit S phase. This dynamic phospho-regulation integrates nutrient sensing via amino acids and growth factors with cell cycle checkpoints, ensuring pyrimidine pools align with proliferative states in rapidly dividing tissues like embryonic epithelia and hematopoietic progenitors. Dysregulation manifests as elevated Ser1859 phosphorylation in prostate adenocarcinoma and castration-resistant subtypes, correlating with mTOR hyperactivation and biochemical relapse through unrestrained nucleotide synthesis fueling genomic instability.

Background

Phospho-CAD (Ser1859) functions as the activated form of the multifunctional CAD enzyme complex that catalyzes the initial three steps of de novo pyrimidine biosynthesis, converting glutamine to carbamoyl phosphate, then to carbamoyl aspartate, and finally to dihydroorotate en route to UMP production essential for RNA and DNA synthesis. CAD assembles as a hexameric structure with distinct catalytic domains for glutamine amidotransferase (GLNase), carbamoyl-phosphate synthetase (CPSase), aspartate transcarbamoylase (ATCase), and dihydroorotase (DHOase), where phosphorylation at Ser1859 within the CPSase domain stabilizes inter-subunit contacts to enhance enzymatic flux through allosteric relief of feedback inhibition by UTP. mTORC1 pathway activation transmits growth signals through S6K1 kinase to deposit this phosphate mark, promoting CAD oligomerization that accelerates glutamine-dependent CPSase activity and ATCase condensation while coordinating with pentose phosphate pathway flux to match nucleotide demand during S-phase progression. ERK1/2 phosphorylation at Thr456 drives nuclear translocation upon G1/S entry, positioning phospho-CAD to support replication fork progression and chromatin remodeling, with subsequent PKA-mediated Ser1406 phosphorylation facilitating cytoplasmic return as cells exit S phase. This dynamic phospho-regulation integrates nutrient sensing via amino acids and growth factors with cell cycle checkpoints, ensuring pyrimidine pools align with proliferative states in rapidly dividing tissues like embryonic epithelia and hematopoietic progenitors. Dysregulation manifests as elevated Ser1859 phosphorylation in prostate adenocarcinoma and castration-resistant subtypes, correlating with mTOR hyperactivation and biochemical relapse through unrestrained nucleotide synthesis fueling genomic instability.

References
https://pubmed.ncbi.nlm.nih.gov/23594158/ https://pubmed.ncbi.nlm.nih.gov/23429704/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%